Replies to post #128960 on Biotech Values

[oc631]

I picked up 500 shares at 66 FWIW.

[DewDiligence]

What do you find so appealing about ABT's all-oral offering?

Nothing specific in a technical sense; rather, what I find notable is ABT’s use of language in the slide in #msg-68216224.

Unlike small biotech companies, ABT does not typically engage in hyperbole when describing clinical outcomes, so it’s reasonable to infer that ABT is indeed seeing some very impressive results from the all-oral HCV combinations it is testing.